These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2110711)

  • 1. Comparative study of the therapeutic effects of glibenclamide or the fixed combination of glibenclamide-phenformin with those of gliclazide or chlorpropamide.
    Raptis AE; Tountas N; Yalouris AG; Hadjidakis D; Zaharis A; Miras K; Raptis SA
    Acta Diabetol Lat; 1990; 27(1):11-22. PubMed ID: 2110711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The glibenclamide-phenformin combination in the therapy of diabetes mellitus].
    Polosa P; Mughini L
    Minerva Med; 1974 Aug; 65(59):383-9. PubMed ID: 4213556
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations].
    Di Cianni G; Benzi L; Ciccarone AM; Cecchetti P; Giannarelli R; Penno G; Navalesi R
    Clin Ter; 1990 Aug 15-31; 134(3-4):187-91. PubMed ID: 2147619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
    Harrower AD
    Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients.
    Raptis AE; Tountas NB; Yalouris AG; Halvatsiotis PG; Raptis SA
    Horm Metab Res; 1996 Feb; 28(2):89-94. PubMed ID: 8867905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.
    Harrower AD
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S65-7. PubMed ID: 1794268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides.
    Seshiah V; Shanker R; Madhavan R; Venkataraman S; Sundaram A; Seshasaianam C; Sankaran JR
    J Assoc Physicians India; 1992 Oct; 40(10):666-8. PubMed ID: 1307353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes.
    Garber A; Marre M; Blonde L; Allavoine T; Howlett H; Lehert P; Cornes M
    Diabetes Obes Metab; 2003 May; 5(3):171-9. PubMed ID: 12681024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
    BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
    Comaschi M; Demicheli A; Di Pietro C; Bellatreccia A; Mariz S;
    Diabetes Technol Ther; 2007 Aug; 9(4):387-98. PubMed ID: 17705695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glibenclamide, a new oral antidiabetic].
    Edlén A
    Lakartidningen; 1972 Jan; 69(4):342-3. PubMed ID: 4622487
    [No Abstract]   [Full Text] [Related]  

  • 19. Bed time NPH-insulin plus combined sulfonylurea-biguanide oral therapy for treating refractory non insulin dependent diabetic patients.
    di Cianni G; Benzi L; Ciccarone AM; Cecchetti P; Navalesi R
    Diabete Metab; 1992; 18(6):468-9. PubMed ID: 1297606
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.